Peter Sheldrake

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I. Raynaud, Suzanne A. Eccles, Sonal Patel et al. · Molecular Cancer Therapeutics · 2009 · 270 citations · Full text

Total synthesis of erythromycins. 4. Total synthesis of erythronolide B

E. J. Corey, Sunggak Kim, Sung-Eun Yoo et al. · Journal of the American Chemical Society · 1978 · 154 citations

Biosynthesis, Engineering, Diversity-oriented Synthesis +9

Total synthesis of erythromycins. 3. Stereoselective routes to intermediates corresponding to C(1) to C(9) and C(10) to C(13) fragments of erythronolide B

E. J. Corey, Eugene J. Trybulski, Lawrence S. Melvin et al. · Journal of the American Chemical Society · 1978 · 115 citations

J. Corey, Engineering, Erythronolide B +11

Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling

Simon R. Stockwell, Georgina Platt, S. Elaine Barrie et al. · PLoS ONE · 2012 · 112 citations · Full text

Reverse Genetics, Molecular Regulation, Molecular Biology +22

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

Sheelagh Frame, Chiara Saladino, Craig MacKay et al. · PLoS ONE · 2020 · 81 citations · Full text